XTX Topco Ltd Makes New Investment in Boston Scientific Co. (NYSE:BSX)

XTX Topco Ltd bought a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,532 shares of the medical equipment provider's stock, valued at approximately $1,134,000.

A number of other institutional investors have also added to or reduced their stakes in BSX. Zacks Investment Management increased its holdings in shares of Boston Scientific by 7.5% in the third quarter. Zacks Investment Management now owns 255,818 shares of the medical equipment provider's stock valued at $21,438,000 after purchasing an additional 17,891 shares during the last quarter. iSAM Funds UK Ltd increased its holdings in shares of Boston Scientific by 144.2% in the third quarter. iSAM Funds UK Ltd now owns 21,966 shares of the medical equipment provider's stock valued at $1,841,000 after purchasing an additional 12,972 shares during the last quarter. National Bank of Canada FI increased its holdings in shares of Boston Scientific by 51.0% in the third quarter. National Bank of Canada FI now owns 666,891 shares of the medical equipment provider's stock valued at $55,885,000 after purchasing an additional 225,221 shares during the last quarter. EP Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 22.0% in the third quarter. EP Wealth Advisors LLC now owns 15,941 shares of the medical equipment provider's stock valued at $1,336,000 after purchasing an additional 2,875 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC acquired a new position in shares of Boston Scientific in the third quarter valued at $1,635,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on BSX. Barclays upped their price objective on shares of Boston Scientific from $78.00 to $86.00 and gave the company an "overweight" rating in a report on Thursday, August 22nd. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Raymond James boosted their target price on shares of Boston Scientific from $91.00 to $94.00 and gave the company a "strong-buy" rating in a research report on Wednesday, September 4th. Bank of America boosted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Finally, Mizuho boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $93.52.

Boston Scientific Trading Up 1.7 %

Shares of Boston Scientific stock traded up $1.51 on Tuesday, hitting $90.23. The stock had a trading volume of 4,610,782 shares, compared to its average volume of 6,002,105. The stock has a 50 day moving average of $87.50 and a 200 day moving average of $81.44. Boston Scientific Co. has a twelve month low of $54.86 and a twelve month high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market capitalization of $132.98 billion, a P/E ratio of 74.55, a PEG ratio of 2.65 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the firm posted $0.50 earnings per share. The firm's revenue was up 19.3% compared to the same quarter last year. Sell-side analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company's stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the sale, the executive vice president now directly owns 34,748 shares of the company's stock, valued at $2,913,967.28. This represents a 16.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock valued at $27,957,676 over the last quarter. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.